$ABTI
ALTEROLA BIOTECH INC.

2022 Form 10-K Financial Statement

#000166357722000372 Filed on June 10, 2022

View on sec.gov

Income Statement

Concept 2022 2021 Q1 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.040M $247.5K $309.5K
YoY Change 1205.33% 725.0% -6.21%
% of Gross Profit
Research & Development $2.430M
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.470M $247.5K $0.00
YoY Change 725.0% -100.0%
Operating Profit -$6.471M
YoY Change
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.470M -$247.5K -$309.5K
YoY Change 1990.47% 725.0% 23.8%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.470M -$247.5K -$309.5K
YoY Change 1990.47% 725.0% 23.8%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$8.403K -$862.80 -$699.70
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 2021 Q1 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.00K $0.00
YoY Change
Cash & Equivalents $519.00
Short-Term Investments
Other Short-Term Assets $10.00K $12.77K $0.00
YoY Change -36.15% -100.0%
Inventory $0.00 $0.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $130.0K $12.77K $0.00
YoY Change -36.15% -100.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $12.00M $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $130.0K $12.77K $0.00
Total Long-Term Assets $12.00M $0.00 $0.00
Total Assets $12.13M $12.77K $0.00
YoY Change -36.15% -100.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $540.0K $100.0K
YoY Change 440.0%
Accrued Expenses $400.0K $350.2K $580.0K
YoY Change -31.03% 25.09% 70.59%
Deferred Revenue
YoY Change
Short-Term Debt $160.0K $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.200M $402.5K $760.0K
YoY Change 57.89% 43.75% 123.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.200M $402.5K $760.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.200M $402.5K $760.0K
YoY Change 57.89% 43.75% 123.53%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.93M $136.00 -$760.0K
YoY Change
Total Liabilities & Shareholders Equity $12.13M $12.77K $0.00
YoY Change -36.15% -100.0%

Cashflow Statement

Concept 2022 2021 Q1 2021
OPERATING ACTIVITIES
Net Income -$6.470M -$247.5K -$309.5K
YoY Change 1990.47% 725.0% 23.8%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $40.00K -$50.00K -$50.00K
YoY Change -180.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K 50.00K 50.00K
YoY Change -120.0%
NET CHANGE
Cash From Operating Activities 40.00K -50.00K -50.00K
Cash From Investing Activities 0.000
Cash From Financing Activities -10.00K 50.00K 50.00K
Net Change In Cash $0.00 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities $40.00K -$50.00K -$50.00K
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow $40.00K -$50.00K -$50.00K
YoY Change -180.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Funds Held Under Reinsurance Agreements Asset
FundsHeldUnderReinsuranceAgreementsAsset
USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
USD
CY2021Q1 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
USD
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
USD
CY2021Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
USD
CY2021 us-gaap Professional Fees
ProfessionalFees
USD
CY2021 us-gaap Salaries And Wages
SalariesAndWages
USD
CY2021 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
USD
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
USD
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
USD
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
USD
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
USD
CY2022 us-gaap Increase Decrease In Intangible Assets Current
IncreaseDecreaseInIntangibleAssetsCurrent
USD
CY2021 us-gaap Increase Decrease In Intangible Assets Current
IncreaseDecreaseInIntangibleAssetsCurrent
USD
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
USD
CY2021 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
USD
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
USD
CY2022 us-gaap Interest Paid
InterestPaid
USD
CY2021 us-gaap Interest Paid
InterestPaid
USD
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
USD
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
USD
CY2021 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
USD
CY2022 us-gaap Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable
AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
USD

Files In Submission

Name View Source Status
0001663577-22-000372-index-headers.html Edgar Link pending
0001663577-22-000372-index.html Edgar Link pending
0001663577-22-000372.txt Edgar Link pending
0001663577-22-000372-xbrl.zip Edgar Link pending
abti-20220331.xsd Edgar Link pending
abti-20220331_cal.xml Edgar Link unprocessable
abti-20220331_def.xml Edgar Link unprocessable
abti-20220331_lab.xml Edgar Link unprocessable
abti-20220331_pre.xml Edgar Link unprocessable
abti10k.htm Edgar Link pending
abti10k_htm.xml Edgar Link completed
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending